Skip to main content

FDA approves Scynexis’ Brexafemme

The product — a treatment for vaginal yeast infections — is expected to be launched in the second half of this year.
Levy

The Food and Drug Administration has greenlighted Scynexis’ Brexafemme (ibrexafungerp) tablets for oral use in patients with vaginal yeast infections.

Scynexis has partnered with Amplity Health to support U.S. commercialization of the treatment.

“The FDA approval of Brexafemme is the culmination of years of work and a significant milestone for Scynexis, marking our evolution to a commercial-stage antifungal company. We are pleased with the approved label, highlighting the unique attributes of Brexafemme, and thrilled to be able to offer a new treatment option to women with vaginal yeast infections,” said Marco Taglietti, president and CEO of Scynexis.

Taglietti added, “We believe ibrexafungerp has significant commercial potential. This first approval in the U.S. is a major step towards building the ibrexafungerp antifungal franchise as we intend to leverage an extended 10-year period of regulatory exclusivity and 14 years of patent protection. We are in a strong financial position to execute on our commercial plans and are committed to advancing our hospital programs to maximize the broad potential of this novel therapeutic class to help patients with serious and often resistant fungal infections.”

David Angulo, chief medical officer of Scynexis, said, “We are pleased to bring this much needed innovation to the antifungal field and to offer a new one-day oral antifungal treatment for vaginal yeast infections to millions of women who could benefit from a new therapeutic option. Brexafemme has a differentiated fungicidal mechanism of action that kills a broad range of Candida species, including azole-resistant strains. We are working on completing our CANDLE study investigating ibrexafungerp for the prevention of recurrent VVC and expect we will be submitting a supplemental NDA in the first half of 2022. We thank all the clinical investigators and patients who participated in our VANISH clinical trials who made this significant advancement possible.”

The commercial launch of the product is scheduled in the second half of this year.

X
This ad will auto-close in 10 seconds